Epigenetics: Technologies and Global Markets
商品番号 : SMB-74663
| 出版社 | BCC Research |
| 出版年月 | 2025年3月 |
| ページ数 | 115 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,650 |
| 種別 | 英文調査報告書 |
Report Highlights
The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029.
エピジェネティクス研究ツールおよび試薬、IVD、治療薬の世界市場は、2024年から2029年にかけて年平均成長率（CAGR）11.8%で成長し、2024年の48億ドルから2029年末までに85億ドルに成長すると予想されています。
Report Scope
This report comprehensively analyzes the global market for epigenetics products, research tools and reagents, epigenetic biomarker-based in vitro diagnostics (IVDs) and epigenetics-targeted therapeutics. It offers both quantitative and qualitative insights to help readers formulate growth strategies, evaluate the market landscape, assess their competitive positions and make informed business decisions regarding epigenetics products and services. The scope of epigenetics-targeted therapeutics includes DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, isocitrate dehydrogenase (IDH) inhibitors and zeste homolog 2 (EZH2) inhibitors.
In this report, BCC Research estimated market data for 2023 (base year) and forecasts values for 2024 through 2029. The research tools and reagents market segmentation is based on the study methods. Epigenetic biomarker-based IVDs market segmentation is based on clinical indications. Epigenetics targeted therapeutics market segmentation is based on drug class. This report also provides regional analyses for epigenetics products.
This report analyzes industry growth drivers, restraints, trends and opportunities in the epigenetics market. The report also covers the competitive landscape and latest trends in epigenetics products. Emerging technologies that impact the epigenetics market are also discussed, along with current information about new products, acquisitions and collaborations related to the epigenetics market.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2023 | ||||||||||||||||
| Forecast period considered | 2024-2029 | ||||||||||||||||
| Base year market size | $4.4 Billion | ||||||||||||||||
| Market size forecast | $8.5 Billion | ||||||||||||||||
| Growth rate | CAGR of 11.8% from 2024 to 2029 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | By Product Type, Study Method, Clinical Indication, Drug Class and Region | ||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and the Rest of the World (RoW) | ||||||||||||||||
| Key Market Drivers |
| ||||||||||||||||
| Companies studied |
| ||||||||||||||||
Report Includes
– 25 data tables and 66 additional tables
– Analyses of the trends in global markets for epigenetics technologies, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
– Estimates of the size and growth forecasts of the global epigenomics market, and a corresponding market share analysis by product type, study method, clinical indication, drug class and region
– Facts and figures pertaining to the market dynamics, technological advancements, regulatory landscape, and the impact of macroeconomic factors
– Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
– Evaluation of recent patent activity and key granted and published patents in the industry
– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
– Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
– Profiles of leading companies, including Bristol-Myers Squibb Co., Les Laboratoires Servier, Exact Sciences Corp., Thermo Fisher Scientific Inc., and Qiagen
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Epigenetics Overview
DNA Methylation
Histone Modification
RNA Modifications
Epigenetic Modulators
Chapter 3 Market Dynamics
Market Dynamics Snapshot
Market Drivers
Rising Prevalence of Cancer and Unmet Need in Oncology
Advances in Analytical Technologies and Tools
Increasing Investment in Biomedical Research
Trend Towards Precision Medicine
Growing Interest in Liquid Biopsy
Market Restraints
From Bench to Bedside: The Translation Gap in Epigenetics
Epigenetic Therapeutics: Limited Clinical Success Against Solid Tumors
Stringent Regulatory Landscape
Market Trends
Combining Epigenetic Modifiers with Other Therapeutic Class
Multi-omics Integration
Long-Read Sequencing in Epigenetic Research
Epigenetic Biomarkers-based Blood Test for Cancer Screening
Chapter 4 Emerging Technologies and Developments
Emerging Technologies
Epigenome Editing
Epitranscriptomics
Bromodomain and Extra-Terminal Domain Inhibitors
Menin Inhibitors
Application Beyond Oncology
Pipeline Analysis
Overview
Novel Epigenetic Therapeutics in Development in Phase 2 and Above
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Epigenetics Research Tools and Reagents Market, by Study Method
Market Overview
Market Size and Forecast
DNA Methylation
Histone Modification
RNA Modification
In Vitro Diagnostics (IVDs) Market, by Clinical Indication
Market Overview
Market Size and Forecast
Epigenetic Therapeutics Market, by Drug Class
Market Overview
Market Size and Forecast
Geographic Breakdown
Epigenetics Research Tools and Reagents Market, by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Competitive Intelligence
Research Tools and Reagents
In Vitro Diagnostics
Therapeutics
Chapter 7 Sustainability in the Epigenetics Market: An ESG Perspective
Introduction to ESG
Key ESG Issues in Epigenetics Pharmaceuticals and Diagnostics Market
Sustainability Practices in Pharmaceuticals Manufacturing
Sustainable Packaging
Key ESG Issues in Epigenetics Research Tools Market
ESG Risk Ratings Score — Understanding the Data
Concluding Remarks
Chapter 8 Appendix
Methodology
Sources
Abbreviations
Company Profiles
ACTIVE MOTIF INC.
BIO-RAD LABORATORIES INC.
BIO-TECHNE
BRISTOL-MYERS SQUIBB CO.
DAIICHI SANKYO CO. LTD.
EXACT SCIENCES CORP.
GUARDANT HEALTH
HOLOGIC INC.
LES LABORATOIRES SERVIER
MERCK KGAA
NUCLEIX
PROMEGA CORP.
QIAGEN
REVVITY INC. (PERKINELMER)
THERMO FISHER SCIENTIFIC INC.
List of Tables
Summary Table : Global Market for Epigenetics Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
Table 1 : Techniques, Advantages and Disadvantages of Common DNA Methylation Analysis Methods
Table 2 : Types of Noncoding (ncRNAs)
Table 3 : Key Programs/Consortiums to Support Epigenetic Research
Table 4 : Epigenetic Biomarker-based Blood Tests Currently Under Clinical Development
Table 5 : Companies Developing Products Based on Epigenome Editing Platforms
Table 6 : BET Inhibitors in Late-Stage Clinical Trials
Table 7 : Menin Inhibitors in Clinical Trials
Table 8 : Novel Epigenetic Therapeutic Candidates in Clinical Trials Phase 2 and Above
Table 9 : Global Market for Epigenetics Research Tools and Reagents, by Study Method, Through 2029
Table 10 : Commercially Available Epigenetic Biomarker-based IVDs for Colorectal Cancer
Table 11 : Commercially Available Epigenetic Biomarker-based IVDs for Bladder Cancer
Table 12 : Commercially Available Epigenetic Biomarker-based IVDs for Cervical Cancer
Table 13 : Commercially Available Epigenetic Biomarker-based IVDs for Other Indications
Table 14 : FDA Breakthrough Device Designated Epigenetic Biomarker-based Clinical Assays Currently Undergoing Clinical Validation
Table 15 : Global Market for Epigenetic Biomarker-based IVDs, by Clinical Indication, Through 2029
Table 16 : Commercially Available DNMT Inhibitors
Table 17 : Commercially Available HDAC Inhibitors
Table 18 : Commercially Available IDH Inhibitors
Table 19 : Commercially Available EZH2 Inhibitors
Table 20 : Global Market for Epigenetic Therapeutics, by Drug Class, Through 2029
Table 21 : Global Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Region, Through 2029
Table 22 : North American Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
Table 23 : North American Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029
Table 24 : European Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
Table 25 : European Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029
Table 26 : Asia-Pacific Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
Table 27 : Asia-Pacific Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, Through 2029
Table 28 : RoW Market for Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, Through 2029
Table 29 : Global Market Shares of Epigenetic Biomarkers-based IVDs, by Company, 2023
Table 30 : Commercially Available Epigenetics-Targeted Drugs
Table 31 : Key Sustainability Practices in the Pharmaceuticals Industry
Table 32 : ESG Risk Ratings of Key Companies in the Epigenetics Market, 2024
Table 33 : Ethos Impact Inc. Score Card for Key Companies in the Epigenetics Market, 2024
Table 34 : Information Sources for this Report
Table 35 : Abbreviations Used in the Report
Table 36 : Active Motif Inc.: Company Snapshot
Table 37 : Active Motif Inc.: Product Portfolio
Table 38 : Active Motif Inc.: News/Key Developments, 2022
Table 39 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 40 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
Table 41 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 42 : Bio-Rad Laboratories Inc.: News/Key Developments, 2023 and 2024
Table 43 : Bio-Techne: Company Snapshot
Table 44 : Bio-Techne: Financial Performance, FY 2022 and 2023
Table 45 : Bio-Techne: Product Portfolio
Table 46 : Bio-Techne: News/Key Developments, 2023
Table 47 : Bristol-Myers Squibb Co.: Company Snapshot
Table 48 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 49 : Bristol-Myers Squibb Co: Product Portfolio
Table 50 : Daiichi Sankyo Co. Ltd.: Company Snapshot
Table 51 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 52 : Daiichi Sankyo Co. Ltd.: Product Portfolio
Table 53 : Daiichi Sankyo Co. Ltd.: News/Key Developments, 2022-2024
Table 54 : Exact Sciences Corp.: Company Snapshot
Table 55 : Exact Sciences Corp.: Financial Performance, FY 2022 and 2023
Table 56 : Exact Sciences Corp.: Product Portfolio
Table 57 : Exact Sciences Corp.: News/Key Developments, 2023 and 2024
Table 58 : Guardant Health: Company Snapshot
Table 59 : Guardant Health: Financial Performance, FY 2022 and 2023
Table 60 : Guardant Health: Product Portfolio
Table 61 : Guardant Health: News/Key Developments, 2023 and 2024
Table 62 : Hologic Inc.: Company Snapshot
Table 63 : Hologic Inc.: Financial Performance, FY 2023 and 2024
Table 64 : Hologic Inc.: Product Portfolio
Table 65 : Les Laboratoires Servier: Company Snapshot
Table 66 : Les Laboratoires Servier: Financial Performance, FY 2022 and 2023
Table 67 : Les Laboratoires Servier: Product Portfolio
Table 68 : Les Laboratoires Servier: News/Key Developments, 2023 and 2024
Table 69 : Merck KGaA: Company Snapshot
Table 70 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 71 : Merck KGaA: Product Portfolio
Table 72 : Merck KGaA: News/Key Developments, 2023 and 2024
Table 73 : Nucleix: Company Snapshot
Table 74 : Nucleix: Product Portfolio
Table 75 : Nucleix: News/Key Developments, 2023 and 2024
Table 76 : Promega Corp.: Company Snapshot
Table 77 : Promega Corp.: Product Portfolio
Table 78 : Promega Corp.: News/Key Developments, 2023
Table 79 : Qiagen: Company Snapshot
Table 80 : Qiagen: Financial Performance, FY 2022 and 2023
Table 81 : Qiagen: Product Portfolio
Table 82 : Qiagen: News/Key Developments, 2023 and 2024
Table 83 : Revvity Inc. (PerkinElmer): Company Snapshot
Table 84 : Revvity Inc. (PerkinElmer): Financial Performance, FY 2022 and 2023
Table 85 : Revvity Inc. (PerkinElmer): Product Portfolio
Table 86 : Revvity Inc. (PerkinElmer): News/Key Developments, 2023
Table 87 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 88 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 89 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 90 : Thermo Fisher Scientific Inc.: News/Key Developments, 2024
List of Figures
Summary Figure : Global Market Shares of Epigenetics Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
Figure 1 : Market Dynamics of Epigenetics
Figure 2 : Estimated New Cancer Cases Globally, 2022, 2045 and 2050
Figure 3 : Global Blood Cancer Incidence, by Cancer Type, 2022 vs. 2045
Figure 4 : PubMed Article Count: “Epigenetic,” 2018–2024
Figure 5 : Overcoming Barriers in the Clinical Application of Epigenetics
Figure 6 : PubMed Article Count: “Epitranscriptomic” and “RNA Modification,” 2021-2024
Figure 7 : Trends in Clinical Trials for Epigenetic Therapeutic Agents, by Drug Class, as of December 2024
Figure 8 : Global Market Shares of Epigenetics Research Tools and Reagents, by Study Method, 2023
Figure 9 : Global Market Shares of Epigenetic Biomarker-based IVDs, by Clinical Indication, 2023
Figure 10 : Global Market Shares of Epigenetic Therapeutics, by Drug Class, 2023
Figure 11 : Global Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Region, 2023
Figure 12 : North American Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
Figure 13 : North American Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023
Figure 14 : European Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
Figure 15 : European Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023
Figure 16 : Worldwide Incidence of Blood Cancer Cases, by Region, 2022
Figure 17 : Asia-Pacific Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
Figure 18 : Asia-Pacific Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Country, 2023
Figure 19 : RoW Market Shares of Epigenetic Research Tools and Reagents, IVDs and Therapeutics, by Product Type, 2023
Figure 20 : Principle Competitive Factors in Epigenetics Research Tools Market
Figure 21 : Global Market Shares of Leading Manufacturers of Epigenetics-Targeted Therapeutics, 2023
Figure 22 : Selected Factors Driving ESG
Figure 23 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2023
Figure 24 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2023
Figure 25 : Bio-Techne: Revenue Share, by Business Unit, FY 2023
Figure 26 : Bio-Techne: Revenue Share, by Country/Region, FY 2023
Figure 27 : Bristol-Myers Squibb Co: Revenue Share, by Business Unit, FY 2023
Figure 28 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 29 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 30 : Daiichi Sankyo Co. Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 31 : Exact Sciences Corp.: Revenue Share, by Business Unit, FY 2023
Figure 32 : Exact Sciences Corp.: Revenue Share, by Country/Region, FY 2023
Figure 33 : Guardant Health: Revenue Share, by Business Unit, FY 2023
Figure 34 : Guardant Health: Revenue Share, by Country/Region, FY 2023
Figure 35 : Hologic Inc.: Revenue Share, by Business Unit, FY 2024
Figure 36 : Hologic Inc.: Revenue Share, by Country/Region, FY 2024
Figure 37 : Les Laboratoires Servier: Revenue Share, by Business Unit, FY 2023
Figure 38 : Les Laboratoires Servier: Revenue Share, by Region, FY 2023
Figure 39 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 40 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 41 : Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 42 : Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 43 : Revvity Inc. (PerkinElmer): Revenue Share, by Business Unit, FY 2023
Figure 44 : Revvity Inc. (PerkinElmer): Revenue Share, by Country/Region, FY 2023
Figure 45 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023
Figure 46 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023
BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。
ライセンス別価格表
2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
新価格表
ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 4,650 | USD 5,580 | USD 6,696 | USD 8,035 |
ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,950 | USD 3,540 | USD 4,248 | USD 5,098 |
ライセンスタイプ3
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,500 | USD 3,000 | USD 3,600 | USD 4,320 |
旧価格表
旧ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 5,500 | USD 6,600 | USD7.920 | USD 9,504 |
旧ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 3,500 | USD 4,200 | USD 5,040 | USD 6,048 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- 2-5ライセンス
- 同一企業内5名までレポートファイルのご利用が可能です。
- サイトライセンス
- 同一企業同住所内でレポートファイルのご利用が可能です。
- エンタープライズライセンス
- 同一企業内人数無制限でレポートファイルのご利用が可能です。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後3営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- バイオプラスチックの世界市場と技術 2025-03-07
- 半導体製造調査レビュー 2024年 2025-03-06
- 製造市場レビュー 2024年 2025-03-05
- 計測器とセンサの調査レビュー 2024年 2025-03-05
- 航空宇宙用先端材料の世界市場 2025-03-05
